Asset Details
Do you wish to reserve the book?
Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages
Do you wish to request the book?
Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages
2025
Overview
Despite annual vaccines, Influenza B viruses (IBVs) continue to cause severe infections and have a significant impact and burden on the healthcare system. Improving IBV vaccine effectiveness is a key focus, with various strategies under investigation. In this research, we used a computational design to select wildtype sequences for a multivalent viral-vectored vaccine (rAd-Tri-Vic) targeting the Victoria-like (Vic) hemagglutinin (HA) protein. In mouse models, the vaccine induced strong antibody and T cell responses, providing complete protection against both lineage-specific and cross-lineage (Yamagata-like) lethal challenges. The immune responses remained robust for up to six months, which demonstrated sustained protection. These results highlight the potential of HA-targeted multivalent vaccines to enhance the IBV efficacy and address protection against antigenically diverse IBV strains.
Publisher
MDPI AG,MDPI
Subject
/ Analysis
/ Animals
/ Antibodies, Viral - immunology
/ Antigens
/ Cloning
/ Design
/ Enzymes
/ Female
/ Hemagglutinin Glycoproteins, Influenza Virus - genetics
/ Hemagglutinin Glycoproteins, Influenza Virus - immunology
/ Humans
/ Influenza B virus - genetics
/ Influenza B virus - immunology
/ Influenza Vaccines - genetics
/ Influenza Vaccines - immunology
/ Influenza, Human - immunology
/ Influenza, Human - prevention & control
/ Lectins
/ Mice
/ Orthomyxoviridae Infections - immunology
/ Orthomyxoviridae Infections - prevention & control
/ Orthomyxoviridae Infections - virology
/ Peptides
/ Proteins
/ T cells
/ Vaccines
/ Viruses
